Other Events ·
At its June 22, 2026, Annual Meeting, FibroBiologics, Inc. stockholders approved the 2026 Equity and Incentive…
FBLGFibroBiologics, Inc.
At its June 22, 2026, Annual Meeting, FibroBiologics, Inc. stockholders approved the 2026 Equity and Incentive Compensation Plan, which replaces the 2022 Stock Plan. The new plan provides 2,061,968 shares for equity-based compensation and includes evergreen provisions for annual share increases through 2036. Additionally, stockholders approved the issuance of up to 2,272,728 shares related to outstanding warrants from March 2026 Securities Purchase Agreements and 159,091 shares from a November 2025 engagement letter. Pete O’Heeron was elected as a Class III director, and the appointment of WithumSmith+Brown, PC as the independent auditor was ratified. FibroBiologics, Inc. is a biotechnology company focused on developing therapeutic biologics.